July 17, 2015 : Episode 1

Video

Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
4 experts are featured in this series.
Sandip P. Patel, MD
4 experts are featured in this series.
Michael R. Bishop, MD
Mansi R. Shah, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Related Content
The OncFive: Top 5 Oncology Articles of the Week
January 11th 2025

The OncFive: Top Oncology Articles of the Week of 1/5

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

FDA
January 10th 2025

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Subcutaneous Isatuximab Plus Pd in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com
January 9th 2025

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

lertsakwiman – stock.adobe.com
January 8th 2025

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer